Stock CERO CERO THERAPEUTICS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News CERo Therapeutics Holdings, Inc.

Equities

CERO

US71902K1051

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-21 EDT 		5-day change 1st Jan Change
0.3452 USD +19.03% Intraday chart for CERo Therapeutics Holdings, Inc. -9.13% -96.86%
06-06 CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236 CI
05-17 CERo Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
GL
CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236
GL
CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236
CI
CERo Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
CERo Therapeutics, Inc. Provides Corporate Update for Shareholders
GL
CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes
AQ
PHOX BIOT26 : CERo Therapeutics Investor Presentation
PU
CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Top Premarket Decliners
MT
Top Premarket Gainers
MT
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients
BU
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients
CI
CERo Therapeutics Holdings, Inc. announced that it expects to receive $25 million in funding from Arena Business Solutions Global SPC II, Ltd.
CI
Top Premarket Decliners
MT
Phoenix Biotech Acquisition Completes Merger With CERo Therapeutics
MT
Phoenix Biotech Acquisition Corp. Appoints Brian Atwood as Chief Executive Officer
CI
Phoenix Biotech Acquisition Corp. Announces Executive and Board Changes
CI
Phoenix Biotech Acquisition Corp. Appoints Charles Carter as Chief Financial Officer
CI
Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination
BU
Phoenix Biotech Acquisition Corp.(NasdaqGM:CERO) dropped from NASDAQ Composite Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CERO Stock
  4. News CERo Therapeutics Holdings, Inc.